ASCO Approaches, Anticipation Mounts!
18 May 2012
- Roche’s T-DM1: Triple Threat To Breast Cancer or Another Avastin Disaster?
The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year's 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a "ho's who" of established and insurgent oncology companies. Exciting new data will be presented from biotechs like Medivation and Oncothyreon, who are gearing up for their first shot at regulatory approval, as well as from veteran players like Roche, Bayer and GlaxoSmithKline.
Registering for our Expert Insights is free and only takes a moment.
Following this you'll gain unlimited access to all of the latest, event-driven opinion
put together by our teams of experienced analysts.